HUE053963T2 - Béta-guanidinopropionsav gyógyszerészetileg elfogadható, javított tulajdonságokkal rendelkezõ sói és ezek alkalmazásai - Google Patents
Béta-guanidinopropionsav gyógyszerészetileg elfogadható, javított tulajdonságokkal rendelkezõ sói és ezek alkalmazásaiInfo
- Publication number
- HUE053963T2 HUE053963T2 HUE16840104A HUE16840104A HUE053963T2 HU E053963 T2 HUE053963 T2 HU E053963T2 HU E16840104 A HUE16840104 A HU E16840104A HU E16840104 A HUE16840104 A HU E16840104A HU E053963 T2 HUE053963 T2 HU E053963T2
- Authority
- HU
- Hungary
- Prior art keywords
- beta
- pharmaceutically acceptable
- acceptable salts
- improved properties
- guanidinopropionic acid
- Prior art date
Links
- KMXXSJLYVJEBHI-UHFFFAOYSA-N 3-guanidinopropanoic acid Chemical class NC(=[NH2+])NCCC([O-])=O KMXXSJLYVJEBHI-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562209624P | 2015-08-25 | 2015-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE053963T2 true HUE053963T2 (hu) | 2021-07-28 |
Family
ID=58100994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16840104A HUE053963T2 (hu) | 2015-08-25 | 2016-08-25 | Béta-guanidinopropionsav gyógyszerészetileg elfogadható, javított tulajdonságokkal rendelkezõ sói és ezek alkalmazásai |
Country Status (16)
Country | Link |
---|---|
US (4) | US20170056352A1 (hu) |
EP (1) | EP3340973B1 (hu) |
JP (2) | JP6880023B2 (hu) |
CN (2) | CN108472269B (hu) |
AU (1) | AU2016311368B2 (hu) |
CA (1) | CA2996520A1 (hu) |
DK (1) | DK3340973T3 (hu) |
ES (1) | ES2843561T3 (hu) |
HK (1) | HK1257822A1 (hu) |
HR (1) | HRP20210044T1 (hu) |
HU (1) | HUE053963T2 (hu) |
PL (1) | PL3340973T3 (hu) |
PT (1) | PT3340973T (hu) |
RS (1) | RS61804B1 (hu) |
SI (1) | SI3340973T1 (hu) |
WO (1) | WO2017035331A1 (hu) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10308597B2 (en) | 2014-04-30 | 2019-06-04 | Rgenix, Inc. | Inhibitors of creatine transport and uses thereof |
US20190125745A1 (en) * | 2014-12-17 | 2019-05-02 | Rgenix, Inc. | Treatment and diagnosis of cancer |
US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
WO2018160178A1 (en) * | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
WO2021119316A1 (en) * | 2019-12-11 | 2021-06-17 | Rgenix, Inc. | Methods of treating cancer |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA101653A (en) | 1906-08-30 | 1906-10-23 | Herman Besser | Mould |
US3933797A (en) * | 1972-02-22 | 1976-01-20 | Pfizer Inc. | 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS |
BE794886A (fr) * | 1972-02-22 | 1973-08-02 | Pfizer | Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques |
US3972872A (en) | 1974-09-23 | 1976-08-03 | Pfizer Inc. | 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids |
JP2579323B2 (ja) | 1986-09-10 | 1997-02-05 | シンテックス(ユー・エス・エイ)インコーポレイテッド | ジアミン類の選択的アミジン化 |
US5676978A (en) * | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
CA2028593C (en) * | 1989-10-31 | 2007-08-21 | Douglas R. Brandt | Stabilized enzyme compositions |
DE4334639A1 (de) | 1993-10-11 | 1995-04-13 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten |
US5994577A (en) | 1994-11-23 | 1999-11-30 | Larsen; Scott D. | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
DE793646T1 (de) | 1994-11-23 | 1999-12-30 | Pharmacia & Upjohn Co., Kalamazoo | Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus |
JP3745439B2 (ja) | 1995-07-06 | 2006-02-15 | 花王株式会社 | 皮膚外用剤 |
TW453881B (en) | 1995-10-16 | 2001-09-11 | Kao Corp | Cosmetic composition comprising amide derivatives |
JPH09202710A (ja) * | 1995-11-20 | 1997-08-05 | Kao Corp | しわ改善剤 |
EP0912523A1 (en) | 1996-05-21 | 1999-05-06 | PHARMACIA & UPJOHN COMPANY | Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus |
JP4317599B2 (ja) | 1996-06-26 | 2009-08-19 | 武田薬品工業株式会社 | 徐放性製剤 |
ATE318138T1 (de) | 1998-06-30 | 2006-03-15 | Takeda Pharmaceutical | Pharmazeutisches mittel zur behandlung von diabetes |
EP1656945A1 (en) | 1999-06-05 | 2006-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmaceutical composition comprising oligoarginine |
EP1189623B1 (en) | 1999-06-05 | 2007-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
US6242491B1 (en) | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
US20020082448A1 (en) | 1999-11-08 | 2002-06-27 | The Upjohn Company | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
US7335723B2 (en) | 2001-08-08 | 2008-02-26 | Merck & Co., Inc. | Melanin-concentrating hormone antagonists |
WO2003039449A2 (en) | 2001-11-07 | 2003-05-15 | Medical Research Council | Modulation of dopaminergic neurons |
EP1495046A2 (en) | 2002-01-09 | 2005-01-12 | Merck & Co., Inc. | Selective melanin concentrating hormone type 1 receptor agonists |
US20120245211A1 (en) | 2002-06-04 | 2012-09-27 | Children's Hospital Medical Center | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism |
JP2005528424A (ja) | 2002-06-04 | 2005-09-22 | アビセナ グループ インコーポレイティッド | 脳内エネルギー代謝を調節することによって認知機能障害を治療する方法 |
GB0302882D0 (en) | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
JP4865251B2 (ja) | 2005-05-09 | 2012-02-01 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
DK1909601T3 (da) | 2005-08-02 | 2013-08-26 | Alzchem Ag | Flydende formulering baseret på en guanidineddikesyrekomponent |
WO2008054544A2 (en) | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
WO2008043024A2 (en) | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
ES2364865T3 (es) | 2006-12-11 | 2011-09-15 | Kempharm, Inc. | Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos. |
DE102007004781A1 (de) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels |
JP2010518113A (ja) | 2007-02-08 | 2010-05-27 | ケムファーム・インコーポレーテッド | アンフェタミンおよび他の刺激薬の極性親水性プロドラッグ、およびそれらの製造方法および使用方法 |
US20100179106A1 (en) | 2007-09-07 | 2010-07-15 | Gencia Corporation | Mitochondrial compositions and uses thereof |
DE112009000268T5 (de) | 2008-02-06 | 2011-06-01 | Helm Ag | Prasugrel-Salze mit verbesserten Eigenschaften |
FR2940104B1 (fr) | 2008-12-19 | 2011-08-19 | Oreal | Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin |
BRPI0907287B1 (pt) | 2008-12-19 | 2018-01-02 | L'oréal | "processo de clareamento ou de coloração das fibras queratínicas e dispositivo com vários comportamentos" |
FR2940077B1 (fr) | 2008-12-19 | 2012-07-20 | Oreal | Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante. |
JP5866137B2 (ja) | 2009-04-30 | 2016-02-17 | ロレアル | アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および/または着色ならびに装置 |
WO2011031308A1 (en) | 2009-09-09 | 2011-03-17 | Cytokinetics, Incorporated | Novel combinations |
WO2011033068A1 (en) | 2009-09-18 | 2011-03-24 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
FR2954160B1 (fr) | 2009-12-22 | 2012-03-30 | Oreal | Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere |
CN102781236B (zh) | 2009-12-31 | 2015-01-07 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
DE102010012199A1 (de) | 2010-03-19 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Molekular geprägte Polymere für die Eliminierung von Metaboliten |
FR2958161B1 (fr) | 2010-04-02 | 2012-04-27 | Oreal | Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin |
DK2558577T3 (en) | 2010-04-16 | 2019-04-01 | Nuevolution As | Bi-functional complexes and methods for the preparation and use of such complexes |
EP2560490A1 (en) | 2010-04-21 | 2013-02-27 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
ES2710617T3 (es) | 2010-04-21 | 2019-04-26 | Signature Therapeutics Inc | Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos |
US20110262359A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
AU2010351605C1 (en) | 2010-04-21 | 2015-08-06 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
MX2012012743A (es) | 2010-05-03 | 2012-11-23 | Genentech Inc | Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina. |
WO2011143534A1 (en) | 2010-05-13 | 2011-11-17 | The Mclean Hospital Corporation | Methods for the treatment of psychiatric disorders |
EP2399885A1 (en) | 2010-06-22 | 2011-12-28 | Ulrich Dietz | Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification |
WO2012024611A1 (en) | 2010-08-20 | 2012-02-23 | Natural Alternatives International, Inc. | Methods of treating sarcopenia and frailty |
WO2012047630A2 (en) | 2010-09-27 | 2012-04-12 | Martin Teintze | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use |
US8765115B2 (en) | 2010-12-01 | 2014-07-01 | National Institute of Agrobiological Scienses | Method of treatment of gastrointestinal disorders with IL-10 |
US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
WO2012122412A2 (en) | 2011-03-09 | 2012-09-13 | Signature Therapeutics, Inc. | Compositions for reducing risk of adverse events caused by drug-drug interactions |
RU2608305C2 (ru) | 2011-03-09 | 2017-01-17 | Сигничер Терапьютикс, Инк. | Пролекарства действующих веществ гетероциклическими линкерами |
WO2012138214A1 (en) * | 2011-04-08 | 2012-10-11 | Brewster Lizzy Maritza | Beta-guanidinopropionic acid for the treatment of hypertension |
WO2012173846A2 (en) | 2011-06-06 | 2012-12-20 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CN102850242A (zh) * | 2011-06-27 | 2013-01-02 | 天津天成制药有限公司 | 胍基丙酸硝酸盐的制备方法 |
US8427223B2 (en) | 2011-07-19 | 2013-04-23 | Lsi Corporation | Voltage level translator circuit for reducing jitter |
ES2621306T3 (es) | 2011-07-28 | 2017-07-03 | Kempharm, Inc. | Profármacos de metilfenidato, procesos para la obtención y uso de los mismos |
RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
FR2983407B1 (fr) | 2011-12-06 | 2014-01-03 | Oreal | Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration |
JP6450192B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物 |
MX362492B (es) | 2012-02-15 | 2019-01-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos. |
NZ703341A (en) | 2012-06-05 | 2016-11-25 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
US9221789B2 (en) | 2012-06-22 | 2015-12-29 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
AU2013337768B2 (en) * | 2012-10-31 | 2015-07-02 | The Rockefeller University | Treatment and diagnosis of colon cancer |
FR2997846B1 (fr) | 2012-11-09 | 2023-10-20 | Oreal | Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition |
WO2014138492A1 (en) | 2013-03-08 | 2014-09-12 | Solan, LLC | Methods for fabricating graphite-based structures and devices made therefrom |
CN103288685B (zh) * | 2013-07-03 | 2015-02-18 | 郭礼强 | 一种3-胍基丙酸的制备方法 |
US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
-
2016
- 2016-08-24 US US15/245,750 patent/US20170056352A1/en not_active Abandoned
- 2016-08-25 AU AU2016311368A patent/AU2016311368B2/en active Active
- 2016-08-25 SI SI201631048T patent/SI3340973T1/sl unknown
- 2016-08-25 PT PT168401040T patent/PT3340973T/pt unknown
- 2016-08-25 EP EP16840104.0A patent/EP3340973B1/en active Active
- 2016-08-25 PL PL16840104T patent/PL3340973T3/pl unknown
- 2016-08-25 DK DK16840104.0T patent/DK3340973T3/da active
- 2016-08-25 WO PCT/US2016/048643 patent/WO2017035331A1/en active Application Filing
- 2016-08-25 RS RS20210023A patent/RS61804B1/sr unknown
- 2016-08-25 HU HUE16840104A patent/HUE053963T2/hu unknown
- 2016-08-25 CN CN201680057402.2A patent/CN108472269B/zh active Active
- 2016-08-25 CN CN202111189796.6A patent/CN114057611A/zh active Pending
- 2016-08-25 CA CA2996520A patent/CA2996520A1/en active Pending
- 2016-08-25 ES ES16840104T patent/ES2843561T3/es active Active
- 2016-08-25 JP JP2018529503A patent/JP6880023B2/ja active Active
- 2016-09-30 US US15/281,329 patent/US9827217B2/en active Active
-
2017
- 2017-10-27 US US15/795,540 patent/US10512623B2/en active Active
-
2019
- 2019-01-04 HK HK19100174.7A patent/HK1257822A1/zh unknown
- 2019-11-06 US US16/675,669 patent/US20200138759A1/en not_active Abandoned
-
2021
- 2021-01-12 HR HRP20210044TT patent/HRP20210044T1/hr unknown
- 2021-04-30 JP JP2021077099A patent/JP7134294B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
PL3340973T3 (pl) | 2021-06-14 |
PT3340973T (pt) | 2021-01-19 |
EP3340973A4 (en) | 2019-04-03 |
JP6880023B2 (ja) | 2021-06-02 |
WO2017035331A1 (en) | 2017-03-02 |
KR20180059446A (ko) | 2018-06-04 |
EP3340973A1 (en) | 2018-07-04 |
US9827217B2 (en) | 2017-11-28 |
US20180243248A1 (en) | 2018-08-30 |
ES2843561T3 (es) | 2021-07-19 |
JP2018531280A (ja) | 2018-10-25 |
CA2996520A1 (en) | 2017-03-02 |
SI3340973T1 (sl) | 2021-07-30 |
JP2021121597A (ja) | 2021-08-26 |
EP3340973B1 (en) | 2020-10-14 |
HRP20210044T1 (hr) | 2021-04-30 |
US10512623B2 (en) | 2019-12-24 |
AU2016311368A1 (en) | 2018-03-29 |
AU2016311368B2 (en) | 2020-10-08 |
DK3340973T3 (da) | 2021-01-11 |
US20170056352A1 (en) | 2017-03-02 |
US20200138759A1 (en) | 2020-05-07 |
US20170056353A1 (en) | 2017-03-02 |
JP7134294B2 (ja) | 2022-09-09 |
CN108472269B (zh) | 2021-11-02 |
CN108472269A (zh) | 2018-08-31 |
CN114057611A (zh) | 2022-02-18 |
RS61804B1 (sr) | 2021-06-30 |
HK1257822A1 (zh) | 2019-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301217I2 (nl) | tirzepatide en farmaceutisch aanvaardbare zouten daarvan | |
NO2022046I1 (no) | Berotralstat and pharmaceutically acceptable salts thereof | |
HUS2100006I1 (hu) | Avapritinib és gyógyászatilag elfogadható sói | |
IL291517A (en) | Administration of cftr boosters containing deuterium | |
HK1257822A1 (zh) | 性質改善的β-胍基丙酸的藥學上可接受的鹽及其用途 | |
ZA201707981B (en) | Compositions of obeticholic acid and methods of use | |
HK1258062A1 (zh) | 給予惡拉戈利的方法 | |
HK1223628A1 (zh) | β- 新的 -酮- β-烷基膽烷酸衍生物在製備奧貝膽酸以及其在醫藥領域的用途 | |
IL253796A0 (en) | Therapeutically active compounds and methods of use | |
IL251246A0 (en) | Therapeutically active compounds and methods of use | |
HK1254055A1 (zh) | 製備奧貝膽酸及其衍生物的方法 | |
EP3096763A4 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
HK1258349A1 (zh) | Hppd變體及使用方法 | |
SG11201609254YA (en) | Therapeutic placental compositions, methods of making and methods of use | |
IL282482A (en) | Variants of protoxin-II and methods of use | |
IL282508A (en) | Variants of protoxin-II and methods of use | |
EP3109230A4 (en) | Class of carboxylic acid derivatives and use thereof in preparation of prodrugs | |
IL254783A0 (en) | Combinations for deworming methods for using them | |
IL262405A (en) | Methods for the preparation of obeticholic acid and derivatives thereof | |
PL3022215T3 (pl) | Stabilizowana postać Tetrofosminy i jej zastosowanie | |
TWI559918B (en) | Use of gallic acid and its pharmaceutically acceptable salt | |
HK1251558A1 (zh) | 新的酰亞胺衍生物及其作為藥物的用途 | |
SG11201708527RA (en) | Manufacture of organopolysulfides and salts thereof | |
EP3386501C0 (de) | Analgetische zusammensetzungen mit nanocarriern und ihre verwendung | |
GB201509277D0 (en) | Production of 3-alkylphenols and uses thereof |